112281-28-4

Basic information

• Product Name: 5-(2-Oxiranyl)-8-(phenylMethoxy)-2(1H)-quinolinone
• Synonyms: 5-(2-Oxiranyl)-8-(phenylMethoxy)-2(1H)-quinolinone
• CAS NO: 112281-28-4
• Molecular Formula: C₁₈H₁₅NO₃
• Molecular Weight: 293
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 112281-28-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 114-116 °C
• Boiling Point: 556.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.298±0.06 g/cm3(Predicted)
• Solubility: Chloroform
• PKA: 10.92±0.70(Predicted)
• CAS DataBase Reference: 5-(2-Oxiranyl)-8-(phenylMethoxy)-2(1H)-quinolinone(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-Oxiranyl)-8-(phenylMethoxy)-2(1H)-quinolinone(112281-28-4)
• EPA Substance Registry System: 5-(2-Oxiranyl)-8-(phenylMethoxy)-2(1H)-quinolinone(112281-28-4)

Safety Data

• Hazardous Substances Data: 112281-28-4(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 112281-28-4 differently. You can refer to the following data:
1. 5-(2-Oxiranyl)-8-(phenylMethoxy)-2(1H)-quinolinone is used in the preparation of quinolones, benzoxazolones, and benzoxazinones as β agonists for the treatment of respiratory diseases
2. Used in the preparation of quinolones, benzoxazolones, and benzoxazinones as β agonists for the treatment of respiratory diseases

Upstream product

• 93609-84-8 5-acetyl-8-benzyloxy-1H-quinolin-2-one 
• 62978-73-8 5-acetyl-8-hydroxy-2(1H)-quinolinone 
• 148-24-3 8-quinolinol 
• 4053-44-5 5-(hydroxymethyl)-8-hydroxyquinoline 
• 15450-72-3 2-oxo-1,2-dihydroquinolin-8-yl acetate 
• 1127-45-3 8-Hydroxyquinoline-N-oxide 
• 66546-38-1 8-(benzyloxy)carbostyril-5-carboxaldehyde 
• 2181-42-2 trimethylsulphonium iodide 
• 956234-40-5 8-(benzyloxy)-5-(2-bromo-1-hydroxyethyl)quinolin-2(1H)-one 
• 100331-89-3 8-benzyloxy-5-(2-bromoacetyl)-1H-quinolin-2-one 
• 869868-63-3 8-benzyloxy-5-(2-chloro-1-hydroxy-ethyl)-1H-quinolin-2-one 
• 108835-26-3 8-(benzyloxy)-5-(hydroxymethyl)quinoline N-oxide 
• 108835-27-4 8-(benzyloxy)quinoline-5-carboxaldehyde N-oxide 
• 108835-25-2 8-(benzyloxy)-5-(hydroxymethyl)quinoline 

Downstream Products

• 226991-44-2 2-[2-hydroxy-2-[8-(benzyloxy)-2(1H)-quinolinonyl]-ethylamino]propane 
• 120551-46-4 5-{2-[2-(4-Amino-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-8-hydroxy-1H-quinolin-2-one 
• 108835-37-6 5-<2-<<3-<4-(bromoacetamido)phenyl>-2-methylprop-2-yl>amino>-1-hydroxyethyl>-8-hydroxycarbostyril hydrobromide 
• 128232-11-1 5-<2-<<1-(4-iodophenyl)-2-methylprop-2-yl>amino>-1-hydroxyethyl>-8-hydroxycarbostyril 
• 861841-84-1 1-{3-[2-(8-benzyloxy-2-oxo-1,2-dihydro-quinolin-5-yl)-2-hydroxy-ethylamino]-3-methyl-butyl}-4,4-diethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
• 869535-95-5 8-benzyloxy-5-{1-hydroxy-2-[1-(4-methoxybenzyl)cyclopropylamino]ethyl}-1H-quinolin-2-one 

Relevant articles and documents

Synthesis and biological evaluation of β2-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold

A new series of β2-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold was synthesized. Evaluation of the compounds using cell assays and an in vitro guinea pig trachea relaxation assay showed that 8-hydroxy-5-(2-hydroxy-1-((4-hy

Beta2-receptorexcitant and preparation method and application thereof

The invention relates to a following formula I showed compound in a free form, a salt form or a solvated form and having a beta2-receptor exciting effect. II and III are contained in R1, Ar are following formula groups IV and V, definition of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R13, R14, R15, R16, m and o is shown in the description. The invention further relates to a preparation method of the compound and application of a compound serving as a drug, in particular to treatment of diseases such as a chronic obstructive pulmonary disease, asthma and heart failure the aspects of a respiratory and cardiovascular system and a cardiovascular system.

Beta agonists for the treatment of respiratory diseases

The present invention relates to compounds of general formula 1 wherein the groups n, A, B, R1, R2 and R3 may have the meanings given in the claims and in the specification, processes for preparing them, and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.